How Process Monitoring Tunnels Ensure Product Quality and Improve Process Performance

With a process monitoring tunnel you can monitor 100s of CPPs in a single graphical interface that captures the overall health – both past and present – of your bioprocess and reliably predicts its future health.

Unlock the value of a complete solution for viral vector production

• While gene therapies can offer remarkable outcomes for patients, realizing their full potential requires an efficient workflow for viral vector production.
• Faced with limited process development and manufacturing expertise, gene therapy innovators can partner with integrated solution providers to fill these gaps and ensure a robust, optimized, and scalable viral vector production process.
• An integrated solution provider offers significant advantages in contrast to an assemblage of multiple suppliers focused on individual workflow steps which may lack a holistic view of operations.

Biopharmaceutical Application Guide

Biopharmaceutical Application Guide helps overcome process challenges

Take a few minutes and navigate through our mAb, ADC, mRNA, Vaccine, and Cell and Gene Therapy process templates. Go ahead and dive into each unit operation to uncover the best option for your process.

Maximize AAV Vector Production from Suspension HEK293 Cells

• Viral vectors are the most reliable and sought-after method for gene delivery.
• Use of adherent cell culture for manufacturing these vectors, however, can lead to limited cell growth, lower productivity, and necessitate use of animal-derived media supplements which increase the risk of introducing adventitious agents.
• The VirusExpress® 293 AAV production platform reduces risk and accelerates timelines with use of chemically defined animal component-free cell culture media that has been optimized for viral vector manufacturing.

Raffle program

If you’re a biotech company and part of a Bio-cluster organization, simply complete the form in this article to take a chance to win our latest cell counter scepter v3.0!

Vaccines Technology Transfer: the foundation for a new era of vaccine production

This whitepaper provides an overview of the technology transfer process and describes the development and optimization of a platform to manufacture a vaccine for tropical diseases.

Scientist sitting a desk, in a lab, smiling, using a bioprocessing software to help with 21 CFR part 11 compliance

What to Know About Data Management and 21 CFR Part 11 and EudraLex Annex 11 Compliance

21 CFR Part 11 and Annex 11’s purpose is to ensure electronic records and signatures are equivalent to paper-based records and handwritten signatures. Beyond proving equivalency, software used for electronic records and signatures offer benefits like access control, audit trails, data integrity, and easy search and retrieval of information.

How to increase upstream AAV and lentiviral vector titers and ensure scalability?

• Cell and gene therapies have delivered remarkable outcomes for patients with a wide variety of diseases and conditions.
• These therapies rely on adeno-associated viral (AAV) vectors and lentiviral vectors and are essential for delivery of genetic material into target cells.
• Use of adherent cell cultures for vector production are limited in terms of scalability and have historically relied on media formations that were not optimized and supplemented with fetal bovine serum.
• In contrast, suspension culture systems deliver significant benefits for upstream viral vector production processes including higher AAV and lentivirus vector titers and robust scalability.

Vaccine Maker’s Toolkit: Strategies For Manufacturing And Supply Management

This collection of insights, produced through a partnership between

Merck KGaA, Darmstadt, Germany
,
MilliporeSigma
and Bioprocess Online, highlights strategies and guidance to ensure reliable biomanufacturing capacity and supply chains for the delivery of health technologies like vaccines, even during crisis conditions.

Coming Full Circle with Biopharma Recycling

This post discusses the environmental challenges posed by the Biopharmaceutical industry’s heavy reliance on single-use systems and the resulting plastic waste. It highlights the industry’s quest for sustainable solutions through advanced recycling methods to achieve circularity.

Scroll to Top